Status:
UNKNOWN
Study of DC-CIK to Treat Colorectal Cancer
Lead Sponsor:
Guangxi Medical University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
Detailed Description
60 patients with stage Ⅲ CRC, who had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, and got complete response (CR), will be randomly divided i...
Eligibility Criteria
Inclusion
- Male or female patients ≥ 18 years of age;
- CRC with histological diagnose, and had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy and got complete response (CR) with imaging;
- Patients who have a life expectancy of at least 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
- The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L);
- The ECG results were normal, and the liver and kidney were functional.
Exclusion
- Patients who had distant metastases;
- Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
- Patients who were pregnant or lactating;
- ECOG perform status ≥ 2;
- Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01839539
Start Date
March 1 2013
End Date
March 1 2018
Last Update
April 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangxi Medical University
Nanning, Guangxi, China, 530000